(NASDAQ: LTRN) Lantern Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Lantern Pharma's earnings in 2025 is -$20,781,213.On average, 1 Wall Street analyst forecast LTRN's earnings for 2025 to be -$20,059,589, with the lowest LTRN earnings forecast at -$20,059,589, and the highest LTRN earnings forecast at -$20,059,589.
In 2026, LTRN is forecast to generate -$12,294,587 in earnings, with the lowest earnings forecast at -$12,294,587 and the highest earnings forecast at -$12,294,587.